• Atmo secures full ownership of core IP for its ingestible gas-sensing capsule
• RMIT University transfers all patents and IP in exchange for an equity stake in Atmo
• Agreement enhances Atmo’s strong IP position ahead of regulatory milestones

MELBOURNE, AUSTRALIA & SAN DIEGO, USA, 15 April 2025:

Atmo Biosciences, a leader in ingestible gas-sensing technology, today announced the successful assignment of its foundational patent portfolio from RMIT University. Under this agreement, RMIT has transferred all patents and associated intellectual property (IP) related to the Atmo Gas Capsule to Atmo Biosciences in exchange for an equity stake in the company. This IP was previously subject to an exclusive license agreement between Atmo and RMIT.

The assignment marks a pivotal step in Atmo’s commercialization journey as it prepares for regulatory submission to the U.S. Food and Drug Administration (FDA) following the successful completion of a pivotal clinical study in a first indication last year.

Originally developed through groundbreaking research by a team at RMIT University, the ingestible gas-sensing capsule was first licensed by Atmo in 2018. Since then, Atmo has advanced the technology from concept to clinical reality—developing, manufacturing, and trialling the device to create a market-ready diagnosticaid  for evaluating gastrointestinal motility disorders. Atmo has since filed additional patents to expand its wholly-owned portfolio of IP in a variety of potential diagnostic and therapeutic applications, further developing the ingestible capsule technology platform.

Academic-Industry Collaboration Driving Innovation

Professor Calum Drummond AO, Deputy Vice-Chancellor Research and Innovation and Vice-President at RMIT, highlighted the importance of the partnership:

“This agreement exemplifies our mission to translate academic research into real-world impact. We are particularly proud that several of our students played instrumental roles in developing this technology at RMIT and have continued to contribute as co-founders at Atmo. The equity component of this agreement strengthens our long-term collaboration, aligning our interests as Atmo continues to expand its platform technology.”

Atmo Biosciences CEO Mal Hebblewhite emphasized the strategic significance of the assignment:

“This is a milestone for Atmo and for RMIT University. Having RMIT as a strategic shareholder reinforces our shared commitment to bringing this innovative technology to market. Full ownership of our core IP further strengthens Atmo’s position as we advance toward regulatory submission and commercialization, ensuring long-term value for our company and the patients we aim to serve.”

About Atmo Biosciences

Atmo Biosciences is a medical device and digital health company commercializing an ingestible, gas-sensing capsulethat provides real-time insights into gut health. The Atmo Gas Capsule measures whole and regional gut transit times, to aid gastroenterologists in diagnosing gut motility disorders. Atmo strives to improve the quality of life for the many sufferers of common and debilitating gastrointestinal disorders and diseases, providing clinicians and researchers with tools that deliver actionable insights regarding gastrointestinal dysfunction. The gas-sensing capsule is currently being used in research applications in multiple clinical trials around the world.

For more information, visit www.atmobiosciences.com.

The Atmo Gas Capsule System is pending FDA 510(k) clearance and is not available for sale. The Atmo Gas Capsule System is an investigational device exclusively for use in clinical research.